Skip to main content

Genital Warts

Current and Future Management Options

Abstract

Genital warts are a cosmetic nuisance. They are caused by low-risk human papillomavirus types, have no oncogenic potential and are not linked to cervical cancer. However, they often cause significant psychological morbidity. Treatments are aimed at eradicating the unsightly lesions and stimulating the immune system to generate clearance and prevent recurrence. Commonly used physical treatment methods include cryotherapy, trichloroacetic acid, laser, and electrocautery. However, many patients respond extremely well to home therapies with either podophyllotoxin or imiquimod. Patients prefer the comfort and dignity of home treatment, and this should be the first-line of treatment for the majority of patients. A routine screen for sexually transmitted infections is appropriate in most cases. Detailed explanation and reassurance are of paramount importance in reducing the psychological distress associated with this unpleasant genital condition.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

References

  1. 1.

    Wilson J. Treatment of genital warts: what’s the evidence?. Int J STD AIDS. 2002; 13: 216–20

    PubMed  Article  Google Scholar 

  2. 2.

    Szarewski A, Cuzick J. Smoking and cervical neoplasia: a review of the evidence. J Epidemiol Biostat. 1998; 3: 229–56

    Google Scholar 

  3. 3.

    Koutsky L, Galloway DA, Holmes KK. Epidemiology of genital human papilloma virus infection. Epidemiol Rev. 1988; 10: 122–63

    PubMed  CAS  Google Scholar 

  4. 4.

    O’Mahony C, Law C, Gollnick HPM, et al. New patient-applied therapy for anogenital warts is rated favourably by patients. Int J STD AIDS. 2001; 12: 565–70

    PubMed  Article  Google Scholar 

  5. 5.

    von Krogh G, Lacey CJ, Gross G, et al. European guideline for the management of anogenital warts. Int J STD AIDS. 2001; 12 Suppl. 3: 40–7

    Article  Google Scholar 

  6. 6.

    Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National Guidelines for the management of anogenital warts. Sex Transm Infect. 1999; 75 Suppl. 1: 71–5

    Google Scholar 

  7. 7.

    Centres for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep. 2002; 51: 53–7

    Google Scholar 

  8. 8.

    Miller RL, Gerest JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999; 21: 1–14

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    O’Mahony C. Difficult wart cases: use of imiquimod cream 5%. Int J STD AIDS. 2001; 12: 400–3

    PubMed  Article  Google Scholar 

  10. 10.

    O’Mahony C. Management of imiquimod induced erythema. HPV Today. 2004; 4: 15

    Google Scholar 

  11. 11.

    Kaspari M, Gutsmer R, Kaspari T, et al. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol. 2002; 147: 757–9

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

Dr O’Mahony has received lecture fees from Steifel — manufacturers of Warticon (podophyllotoxin) and 3M Pharmaceuticals — manufacturers of Aldara (imiquimod).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Colm O’Mahony.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

O’Mahony, C. Genital Warts. Am J Clin Dermatol 6, 239–243 (2005). https://doi.org/10.2165/00128071-200506040-00004

Download citation

Keywords

  • Cervical Cancer
  • Cervical Intraepithelial Neoplasia
  • Imiquimod
  • Genital Wart
  • Podophyllotoxin